$1.7 Trillion Dollars. $54 Billion in Profits, 10 Million Fewer People.

In 2025, 7 health insurance conglomerates collected nearly $1.7 trillion in revenue and reported more than $54 billion in profits while covering 10 million fewer people than the year before. Those figures demand attention because they expose a structural truth about American health insurance. Revenue growth no longer depends on covering more lives. It depends on extracting more money per life and routing public dollars through increasingly consolidated corporate structures.  

The companies at the center of this story are UnitedHealth Group, CVS Health which owns Aetna, Cigna, Elevance which operates as Anthem in several states, Humana, Centene, and Molina. Together they represent the gravitational core of the private insurance market. From 2024 to 2025 their combined revenues rose by $175 billion. Since 2015 their revenues have increased by roughly 300%, driven largely by mergers and acquisitions rather than organic enrollment growth.  

At the same time, employer sponsored family coverage reached an average annual cost of $26,993 in 2025, up from $25,572 in 2024 and 54% higher than the $17,545 average in 2015. Deductibles and cost sharing rose more than 50% over that same period.  

Those numbers clarify the present moment. We no longer debate whether coverage costs too much. We debate how much more employers, workers, and taxpayers will tolerate before the arrangement collapses under its own weight.

The shift toward government funded programs stands out as the most consequential development. UnitedHealthcare now derives 77% of its revenue from Medicare Advantage and Medicaid even though it enrolls nearly twice as many people in commercial plans. All of its enrollment growth since 2015 has occurred in those public programs. It covered 80,000 fewer commercial members in 2025 than it did in 2015.  

Humana, Centene, and Molina show even heavier dependence on taxpayer funded revenue. Centene recorded a $7.6 billion loss in 2025 after expanding aggressively in Medicaid. Humana reported a loss approaching $1 billion in the fourth quarter of 2025 after concentrating its strategy around Medicare Advantage.  

Cigna moved in the opposite direction. It exited Medicare Advantage and leaned further into pharmacy benefit management after acquiring Express Scripts. CVS Health built a similar model around CVS Caremark and Aetna. UnitedHealth built Optum into a vertically integrated delivery and pharmacy platform. Together, Express Scripts, CVS Caremark, and Optum Rx now control roughly 80% of the pharmacy benefit market.  

These shifts illustrate a deeper structural pivot. Insurance companies increasingly function as conglomerates that own physician practices, specialty pharmacies, clinics, data platforms, and care management subsidiaries. UnitedHealth now classifies approximately 27% of its revenues as intercompany eliminations, a percentage that has risen each year as it steers health plan enrollees into Optum owned delivery assets.  

Vertical integration allows insurers to capture margin at multiple points along the care continuum. Premiums enter the system. Claims payments move across corporate divisions. Revenue appears on one side of the ledger while costs shift inside the same corporate family. For patients and employers, the transaction looks like coverage. For shareholders, it looks like yield management.

Wall Street evaluates these companies through metrics such as medical loss ratio and earnings per share. Medical loss ratio measures the percentage of premium revenue spent on claims. When that percentage rises, investors interpret the increase as deterioration in profitability. When that percentage falls, investors reward the company with higher share prices.  

The language matters. Insurers classify paying claims as a loss. That framing reflects the underlying incentive structure. Every approved claim reduces margin. Every denied or delayed claim protects it.

During the pandemic in 2020, many insurers saw their medical loss ratios dip below statutory minimums as patients deferred elective care. Those years produced unusually high profits. As deferred care returned, medical loss ratios rose and share prices declined. Investors responded by pressuring executives to restore margin.  

Executives have several levers. They can raise premiums above last year’s increases. They can narrow provider networks by excluding physicians and hospitals they do not own or control. They can increase deductibles and coinsurance. They can mandate additional referrals and prior authorizations. They can reduce payments to providers. They can remove members from plans that appear financially unattractive.  

None of those actions violate the law in isolation. Each one flows directly from fiduciary obligations to shareholders. Together they shape the lived experience of coverage in the United States.

I learned early that process often outruns care. In January 1996 I spent a week in a hospital bed while my parents negotiated coverage terms with insurers who spoke in procedural language. No one described the conversation as harm. They described it as policy compliance. The outcome still landed on a body.

That pattern persists. Employers absorb higher premiums and shift costs to workers. Workers postpone care until deductibles reset. Taxpayers finance the expansion of Medicare Advantage and Medicaid managed care while private plans consolidate market power. Investors monitor basis point changes in medical loss ratio and demand corrective action.

Industry leaders defend this structure by arguing that private plans deliver efficiency and innovation. They point to care management programs, quality scores, and digital tools. They cite the statutory requirement that at least 80% of premium revenue in the individual and small group markets go toward claims and quality improvement. They emphasize that Medicare Advantage offers supplemental benefits beyond traditional Medicare.

Those arguments contain elements of truth. Medicare Advantage plans often include dental and vision coverage that traditional Medicare lacks. Care coordination can reduce duplication. Data analytics can identify high risk patients.

Yet the aggregate financial data tell a more sobering story. Revenues rise. Enrollment in commercial plans shrinks. Public dollars constitute an increasing share of insurer income. Out of pocket exposure for families climbs. When medical spending rises, executives announce cost control measures that tighten access.  

If efficiency represented the primary goal, we would expect premiums to moderate as scale increases. Instead, employer sponsored family coverage increased 6% in 2025 alone.  

If competition disciplined pricing, we would expect market entry to counterbalance consolidation. Instead, the 7 largest conglomerates dominate national markets and own substantial portions of the care delivery and pharmacy supply chain.

If public program participation reflected purely mission driven alignment, we would expect balanced portfolios across commercial and government business lines. Instead, companies chase Medicare Advantage growth because federal reimbursement formulas offer predictable revenue streams and risk adjustment mechanisms that can amplify payment.

The shift toward Medicare Advantage deserves particular scrutiny. Plans receive capitated payments from the federal government based on risk scores. Higher documented acuity yields higher payments. Plans therefore invest heavily in coding intensity and risk documentation. Regulators have questioned whether some practices inflate payments beyond actual clinical need.

The issue does not hinge on individual coding decisions. It hinges on structure. When revenue depends on documented risk, organizations allocate resources toward documentation infrastructure. When profit depends on controlling claims expense, organizations allocate resources toward utilization management. Neither priority originates at the bedside.

Pharmacy benefit managers add another layer. When 3 entities control 80% of the pharmacy benefit market, they negotiate rebates, set formularies, and determine which drugs patients can access at which cost sharing levels. They argue that scale allows them to extract price concessions from manufacturers. Critics argue that rebate structures create opacity and misaligned incentives.

Patients experience the system through denials, prior authorization delays, and surprise cost sharing. Clinicians experience it through administrative burden. Employers experience it through annual renewal cycles that resemble auction negotiations. Taxpayers experience it through federal outlays that grow alongside private profits.

Executives often respond that health care costs reflect underlying utilization and technology trends. They note that medical inflation, new therapies, and demographic shifts increase spending pressure. They argue that insurers act as intermediaries that buffer employers and governments from even higher costs.

Intermediation carries value when it aligns incentives toward long term health. It fails when short term earnings per share dominates strategic decision making. In 2025, shareholders sold millions of shares when medical loss ratios rose by a few basis points. That reaction signals where primary accountability resides.  

I spent decades watching the vocabulary of health insurance evolve. In the 1980s we debated managed care. In the 1990s we argued about gatekeepers. In the early 2000s we discussed consumer driven health plans. Today we discuss vertical integration and value based care. The labels change. The incentive structure persists.

The companies in question operate within legal frameworks established by Congress and state legislatures. Policymakers designed Medicare Advantage to harness private sector participation. Lawmakers permit vertical consolidation subject to antitrust review. Regulators enforce minimum medical loss ratio thresholds.

Therefore accountability extends beyond corporate boardrooms. It reaches policymakers who tolerate consolidation. It reaches regulators who accept opaque reporting categories such as intercompany eliminations. It reaches institutional investors who treat medical spending as margin erosion rather than community investment.

The present moment demands attention because enrollment growth in public programs no longer masks structural strain. Companies project enrollment declines and revenue pressure in 2026.  

When growth stalls, organizations intensify cost control. That pressure will not dissipate on its own. It will translate into narrower networks, higher cost sharing, and more aggressive utilization management unless external incentives shift.

What must change?

First, policymakers must align payment structures with measurable health outcomes rather than coding intensity or administrative throughput. Risk adjustment requires rigorous auditing and transparency.

Second, regulators must scrutinize vertical integration with greater precision. Owning physician practices and pharmacy operations creates potential conflicts between clinical judgment and corporate revenue goals. Disclosure and structural safeguards should match the scale of consolidation.

Third, employers and public purchasers must demand clearer accounting of where premium dollars flow inside conglomerates. Intercompany eliminations and internal transfers obscure true cost allocation.

Fourth, investors must recognize that sustainable returns depend on a system that maintains public legitimacy. When families face $26,993 annual premiums and rising deductibles, social license erodes.  

Finally, citizens must understand the mechanics at work. Anger without comprehension produces noise. Comprehension without accountability produces drift. We require both clarity and consequence.

The system performs as designed. It channels premium revenue and taxpayer funds through complex corporate structures that reward cost containment and financial engineering. It labels claims payments as losses. It celebrates basis point improvements in medical loss ratio. It expands into publicly financed markets when commercial enrollment shrinks.

Patients seek care. Employers seek stability. Taxpayers seek stewardship. Shareholders seek return. Those objectives can coexist only if governance structures align them.

Right now they do not.

Continuing on the present course will increase the share of national health spending that flows through consolidated intermediaries while leaving families with rising exposure and clinicians with rising administrative burden. The numbers from 2025 confirm the trajectory.  

We can accept that trajectory as inevitable. Or we can confront the incentives that produce it.

Serious adults in every sector must decide which path they prefer.